Background: Misoprostol has been extensively used in obstetrics and has proved to be a very effective cervical softening agent before termination of pregnancy. The beneficial effects on cervical ripening may make misoprostol a desirable agent for helping cervical dilatation on non pregnant women.
Aim: To compare the efficacy and safety of pre-procedure sublingual misoprostol versus pervaginal misoprostol for relief of pain during and after the HSG procedure.
Materials and methods: Study was initiated after approval from the IEC. There after subject recruitment had done form July 2017 to June 2018 in the department of Obstetrics & Gynaecology (indoor setting) of IPGME&R & SSKM Hospital
Result: We found that association of cervical resistance score vas vs. group was statistically significant (p<0.0001). Association of need for analgesics vs. group was not statistically significant (p=0.11004). Association of any adverse effect vs. group was not statistically significant (p=1.0000). Difference of mean age vs. group was not statistically significant (p=0.0717).
Conclusion: There was no significant difference of pain after the HSG procedure in both the group. The patients who were received sublingual misoprostol had significantly low cervical resistance during the procedure.